As of June 16, 2025, Applied Genetic Technologies Corp (AGTC) reports a Net Margin of -21213.23%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Applied Genetic Technologies Corp's Net Margin
Over recent years, Applied Genetic Technologies Corp's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-06-30 | -21213.23% |
| 2021-06-30 | -11565.80% |
| 2020-06-30 | -1873.06% |
| 2019-06-30 | -4.82% |
| 2018-06-30 | -88.05% |
This slight downward trend highlights how Applied Genetic Technologies Corp manages its overall profitability and cost control over time.
Comparing Applied Genetic Technologies Corp's Net Margin to Peers
To better understand Applied Genetic Technologies Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Applied Genetic Technologies Corp (AGTC) | -21213.23% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
| Vertex Pharmaceuticals Inc (VRTX) | -4.86% |
Compared to its competitors, Applied Genetic Technologies Corp's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.